β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
about
Effects of the ß2-adrenoceptor agonist, albuterol, in a mouse model of anti-MuSK myasthenia gravisAtomoxetine prevents dexamethasone-induced skeletal muscle atrophy in miceBeta-agonist stimulation ameliorates the phenotype of spinal and bulbar muscular atrophy mice and patient-derived myotubes.Ginsenoside Rg1 prevents starvation-induced muscle protein degradation via regulation of AKT/mTOR/FoxO signaling in C2C12 myotubesFormoterol decreases muscle wasting as well as inflammation in the rat model of rheumatoid arthritis.Defining COPD-Related Comorbidities, 2004-2014.BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells.Is Exercise Training Appropriate for Patients With Advanced Heart Failure Receiving Continuous Inotropic Infusion? A Review.Chronic β2 -adrenoceptor agonist treatment alters muscle proteome and functional adaptations induced by high intensity training in young men.Mechanisms underlying enhancements in muscle force and power output during maximal cycle ergometer exercise induced by chronic β2-adrenergic stimulation in men.Role of cyclic AMP sensor Epac1 in masseter muscle hypertrophy and myosin heavy chain transition induced by β2-adrenoceptor stimulation.Muscle-Bone Crosstalk: Emerging Opportunities for Novel Therapeutic Approaches to Treat Musculoskeletal Pathologies.
P2860
Q28539518-0E42C155-509A-42C8-9D3B-494679F14E28Q34573906-BB149E9B-BC06-4EFD-BFEF-46979F601041Q37602169-40FCEAA8-5FD4-48F0-B1F4-BDA915548550Q38638011-5987894D-C7AA-4CFD-8333-04C831BC751EQ39721900-CC3C7E89-0E80-4F73-BBA5-5FC6E44DA5FCQ41443181-66DCF6DA-E87E-410D-B493-0034DD096782Q41613311-18EB3024-A437-4C02-B95F-3AF01DB136C3Q47391460-F446ACB3-2C5C-4939-A6BB-D3F24D013282Q47688453-ADF8F93B-0F87-4759-BD6F-9EB3BB251505Q48160423-BEAFDA6F-90AB-4E47-B616-DFFC9DEB0E09Q52654611-84053BAF-4B52-47CA-817D-EC7E33573DF8Q53005827-2FCCFBD6-F29D-48D8-86C4-0AD885B68DA9
P2860
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
@en
type
label
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
@en
prefLabel
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
@en
P2093
P1476
β2-Adrenergic agonists and the treatment of skeletal muscle wasting disorders.
@en
P2093
Anne-Cécile Durieux
Damien G Freyssenet
Olivier R Joassard
P304
P356
10.1016/J.BIOCEL.2013.06.025
P577
2013-07-08T00:00:00Z